MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Portfolio Companies: Asset Management
Angiogenix
Parents
*Architects: Regenerative Medicine
*Architects: Surgical & Diagnostic Technology _ Vascular, PAD (Peripheral Arterial Disease & CLI (Critical Limb Ischemia)
*Industry: California
*Industry: Northern California & Silicon Valley
*Portfolio Companies: Asset Management
Architects: Sickle Cell and Thalassemia
Children
Angiogenix Completes $12 Million Financing_prnewswire
Angiogenix, Inc. is a privately held, early-stage biotechnology company developing products for regenerative medicine.
Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms, a
Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells)
Burlingame, California
Founded 1997
Help the body produce new blood vessels to increase blood flow
Its lead product ACCLAIM targets chronic ischemia (lack of oxygen in the heart muscle)
restore levels of nitric oxide which helps increase blood flow
Vasotrophin, has shown some promise with increasing blood vessel density.